Apolipoprotein
-
Apolipoprotein Related Products (59)
Related Products (59)
-
COG1410
0 ImagesCOG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease.
-
COG 133 TFA
0 ImagesCOG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM.
-
CS-6253
0 ImagesCS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
-
SGA360
0 ImagesSGA360 suppress inflammatory SAA1 signaling in an AHR-dependent manner through a mechanism that does not require AHR binding to its cognate response element (partial antagonist).
-
Mipomersen sodium scrambled negative control
0 ImagesCat. No.: HY-108764BMipomersen sodium scrambled negative control is the sequence scrambled negative control of Mipomersen sodium.
-
Pelacarsen sodium scrambled negative control
0 ImagesCat. No.: HY-151123CPelacarsen sodium scrambled negative control is the sequence scrambled negative control of Pelacarsen sodium.
-
Zerlasiran sodium scrambled negative control
0 ImagesCat. No.: HY-147425CSynonyms: SLN360 sodium scrambled negative controlZerlasiran (SLN360) sodium scrambled negative control is the sequence scrambled negative control of Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
-
Inaxaplin
0 ImagesSynonyms: VX-147Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.
-
APP-018
0 ImagesSynonyms: D-4FAPP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-density lipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases.
-
Zerlasiran sodium
0 ImagesCat. No.: HY-147425ASynonyms: SLN360 sodiumZerlasiran (SLN360) sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
-
1-Linoleoyl Glycerol
0 ImagesSynonyms: 1-Linoleoyl-rac-glycerol; 1-Monolinolein1-Linoleoyl glycerol is a LpPLA2 inhibitor. 1-Linoleoyl glycerol acts as a precursor for synthesizing various functional lipids, such as phospholipids. 1-Linoleoyl glycerol mitigates inflammation induced by Apolipoprotein CIII (reduction of IL-6).
-
Anselamimab
0 ImagesSynonyms: CAEL-101Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis.
-
APL180 TFA
0 ImagesCat. No.: HY-P6365Purity: 99.31%Synonyms: L-4F TFAAPL180 TFA (L-4F) is an apolipoprotein AI mimetic peptide that enhances the anti-inflammatory activity of high-density lipoprotein (HDL). APL180 can be used in the study of cardiovascular diseases.
-
Pelacarsen sodium
0 ImagesSynonyms: AKCEA-APO(a)-LRx sodium; ISIS 681257 sodium; TQJ230 sodiumPelacarsen sodium (ISIS 681257 sodium) is a GalNAc3-conjugated 2′-MOE-modified antisense oligonucleotide. Pelacarsen sodium reduces apo (a).
-
CS-6253 TFA
0 ImagesCat. No.: HY-P6306APurity: 98.08%CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
-
Lepodisiran
0 ImagesCat. No.: HY-177640CAS No.: 2808361-18-2Synonyms: LY3819469Lepodisiran (LY3819469) is a GalNAc-conjugated, injectable small interfering RNA lipid-lowering agent characterized by rapid hepatic uptake and long-lasting effects. Lepodisiran targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran can be used in research related to atherosclerotic cardiovascular disease.
-
APOL1-IN-1
0 ImagesAPOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD).
-
Opemalirsen sodium
0 ImagesCat. No.: HY-177653ACAS No.: 2639854-33-2Synonyms: AZD2373 sodium, ION-972190 sodiumOpemalirsen sodium is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.
